| Autor: |
Zhaohui Su, Gulick, Roy M., Krambrink, Amy, Coakley, Eoin, Hughes, Michael D., Dong Han, Flexner, Charles, Wilkin, Timothy J., Skolnik, Paul R., Greaves, Wayne L., Kuritzkes, Daniel R., Reeves, Jacqueline D. |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; 12/1/2009, Vol. 200 Issue 11, p1724-1728, 5p, 1 Chart, 1 Graph |
| Abstrakt: |
The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P < .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log10 copies/mL at day 14 and -1.91 versus -0.57 log10 copies/mL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
